Keen Vision Acquisition Corporation Ordinary Shares

KVAC

$11.51

-3.20%

N/A-$0.38

Financial Services

Shell Companies

NASDAQ

Inactive

Keen Vision Acquisition Corporation (KVAC) is a firm founded with the primary objective of finalizing a substantial business transaction. This could involve, ...

Supply Chain of KVAC

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

KVC Sponsor LLC

Adeptus Partners, LLC

Loeb & Loeb LLP

Nelson Mullins Riley & Scarborough LLP

EF Hutton (division of Benchmark Investments, LLC)

Brookline Capital Markets (division of Arcadia Securities, LLC)

D. Boral Capital

Keen Vision Capital (BVI) Limited

KVC Sponsor LLC

IPO Sponsor – provides working capital loans and promissory notes to fund SPAC operations and extensions

Adeptus Partners, LLC

Independent Registered Public Accounting Firm / Auditor

Loeb & Loeb LLP

Issuer's Legal Counsel

Nelson Mullins Riley & Scarborough LLP

Underwriter's Legal Counsel

EF Hutton (division of Benchmark Investments, LLC)

IPO Underwriter / Bookrunner

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

KVC Sponsor LLC

Karpus Management Inc.

Wolverine Asset Management, LLC

The Quarry LP

Yakira Capital Management, Inc.

Medera Inc.

KVC Sponsor LLC

Founder/Sponsor – holds ~77.65% of shares; primary beneficiary of any successful business combination

Mizuho Financial Group, Inc.

NYSE:MFG

Institutional shareholder (~15.02% ownership)

W. R. Berkley Corporation

NYSE:WRB

Institutional shareholder (~13.61% ownership)

Karpus Management Inc.

Institutional shareholder (~5.34% ownership)

Wolverine Asset Management, LLC

Institutional shareholder (~5.27% ownership)

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

Keen Vision Capital (BVI) Limited

Curi Bio Inc.

Medera Inc.

NASDAQ:MDER

KVAC's intended merger target (though the original deal was restructured). Medera is a clinical-stage biopharma developing gene/cell therapies for cardiovascular disease. If KVAC successfully merges with Novoheart (Medera subsidiary), the resulting entity will be closely tied to Medera's ecosystem.

Keen Vision Capital (BVI) Limited

Unconfirmed

The single-family office of CEO Kenneth Wong that serves as the strategic backstop for KVAC's SPAC operations. Not publicly listed but relevant as the sponsor ecosystem.

AstraZeneca plc

NASDAQ:AZN

Key downstream partner of Novoheart/Medera via a long-standing collaboration on human heart-in-a-jar models of HFpEF. Proxy for the commercial potential of the proposed merger target's platform.

Curi Bio Inc.

Unconfirmed

Technology integration partner of Novoheart (Medera subsidiary) for cardiac drug screening analytics. Unlisted private company but representative of Novoheart's partner ecosystem.

Geographic

Region-level exposures that can distort the supply network.

Geographic

United States (Summit, NJ)

British Virgin Islands

Hong Kong / Asia

U.S. Securities and Exchange Commission (SEC)

Keen Vision Acquisition Corporation (BVI entity)

Keen Vision Capital (BVI) Limited

United States (Summit, NJ)

Corporate domicile and regulatory jurisdiction – SEC, Nasdaq listing, US securities law compliance

U.S. Securities and Exchange Commission (SEC)Regulatory oversight

British Virgin Islands

Incorporation jurisdiction – regulatory and corporate governance exposure

Keen Vision Acquisition Corporation (BVI entity)NASDAQ:KVACLegal domicile

Hong Kong / Asia

Sponsor and management nexus – CEO Kenneth Wong is a Hong Kong-based investor; Keen Vision Capital (BVI) Limited is the family office; target search initially focused on Asian businesses

Keen Vision Capital (BVI) LimitedSponsor family office / strategic backer

Global (via proposed Medera/Novoheart operations)

If the Novoheart merger completes, operations would span the US, UK, and Hong Kong across clinical-stage biotechnology R&D

Medera Inc. / Novoheart Group LimitedNASDAQ:MDERProposed merger target

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Other

Critical

KVAC is a pre-revenue SPAC with zero operating business. The sole asset is cash held in trust (~$67M market cap). If no business combination is completed by the July 27, 2026 deadline, the SPAC will be forced to liquidate and return capital to shareholders, resulting in total loss of enterprise value.

Other

Critical

Single proposed transaction risk: KVAC has attempted two merger structures with Medera (original $622.6M deal terminated, replaced with $100M Novoheart LOI). Failure to close either would leave KVAC without a viable target.

Other

High

Sponsor concentration: KVC Sponsor LLC (affiliated with CEO Kenneth Wong) controls ~77.65% of shares, giving insiders dominant voting power in any shareholder matter.

Other

High

Trust redemptions: As the deadline approaches, public shareholders may redeem shares, reducing available trust cash for the business combination or post-merger working capital.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

Interest and Dividend Income from Trust Account

100.0%

$0.0B

KVAC has zero operating revenue. All income is derived from interest and dividends on the cash held in the trust account from the IPO proceeds. There are no product segments, no COGS, and no supplier relationships related to revenue generation.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Keen Vision Acquisition Corporation Ordinary Shares

Supply Chain of KVAC

Upstream

KVC Sponsor LLC

Adeptus Partners, LLC

Loeb & Loeb LLP

Nelson Mullins Riley & Scarborough LLP

EF Hutton (division of Benchmark Investments, LLC)

Brookline Capital Markets (division of Arcadia Securities, LLC)

D. Boral Capital

Keen Vision Capital (BVI) Limited

View More

Downstream

KVC Sponsor LLC

Mizuho Financial Group, Inc.

W. R. Berkley Corporation

Karpus Management Inc.

Wolverine Asset Management, LLC

The Quarry LP

Yakira Capital Management, Inc.

Medera Inc.

Proxies

Medera Inc.

Keen Vision Capital (BVI) Limited

AstraZeneca plc

Curi Bio Inc.

Geographic

United States (Summit, NJ)

British Virgin Islands

Hong Kong / Asia

View More

Supply Chain of KVAC

Upstream

KVC Sponsor LLC

Adeptus Partners, LLC

Loeb & Loeb LLP

Nelson Mullins Riley & Scarborough LLP

EF Hutton (division of Benchmark Investments, LLC)

Brookline Capital Markets (division of Arcadia Securities, LLC)

D. Boral Capital

Keen Vision Capital (BVI) Limited

View More

Downstream

KVC Sponsor LLC

Mizuho Financial Group, Inc.

W. R. Berkley Corporation

Karpus Management Inc.

Wolverine Asset Management, LLC

The Quarry LP

Yakira Capital Management, Inc.

Medera Inc.

Proxies

Medera Inc.

Keen Vision Capital (BVI) Limited

AstraZeneca plc

Curi Bio Inc.

Geographic

United States (Summit, NJ)

British Virgin Islands

Hong Kong / Asia

View More